礼来计划在2027年第一季度提交Retatrutide申请
2026-07-23 10:49:34
据金十数据报道，礼来(LLY.N)计划在2027年第一季度向美国食品药品监督管理局（FDA）提交Retatrutide的生物制剂申请。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
中国财政部拟发行2026年记账式附息（十五期）国债Next article：
礼来：Retatrutide III期试验达主要终点
